Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Nucynta (tapentadol) Immediate-release Oral Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2010

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • Nervous system disorders: headache
  • Psychiatric disorders: hallucination
-
-